Author response for "Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain"
Clara Mazagatos(Instituto de Salud Carlos III), The SARI Sentinel Surveillance RSV Study Group, Susana Monge(Instituto de Salud Carlos III), Daniel Castrillejo(Consejería de Educación de la Junta de Castilla y León), Ana Fernández Ibáñez, Amparo Larrauri(Instituto de Salud Carlos III), Olaia Pérez‐Martínez, Mercedes Rumayor, Jaume Giménez Durán, Virtudes Gallardo García(Consejería de Salud y Consumo), Jacobo Mendioroz(Instituto de Salud Carlos III), Virginia Álvarez Río, Nieves López González‐Coviella, Cristina Ramírez Córcoles(Hospital General Universitario de Albacete), Noa Batalla Rebollo, María Isabel Barranco Boada(Servicio Murciano de Salud), Ana Delia Cebollada Gracia(Servicio Aragonés de Salud), Violeta Ramos Marín(Consejería de Educación de la Junta de Castilla y León)
Cited by 0
Related Papers
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
|PLoS Medicine|2011|303
Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021
|Eurosurveillance|2021|281